Vedolizumab, the antibody against α4β7, which has already been approved for treating IBD, can block the binding of CD4+ T cells to MAdCAM-1 and result in inhibition of the pathogenic recruitment of CD4+ T cells and attenuate hepatic inflammation and fibrosis in a NASH model (186). Here, CD4 is linked to inflammatory bowel disease.